{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:03Z","timestamp":1790649723970,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,5,7]],"date-time":"2012-05-07T00:00:00Z","timestamp":1336348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Laryngoscope"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective\/Hypothesis:<\/jats:title><jats:p>To evaluate the effectiveness of a standardized intranasal bevacizumab injection in treating hereditary hemorrhagic telangiectasia (HHT)\u2010associated epistaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design:<\/jats:title><jats:p>Prospective pilot study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A total dose of 100 mg bevacizumab (25 mg\/mL Avastin) was injected submucosally, 50 mg on each side. A total of 0.5 mL was injected in the sphenopalatine area, upper part of bony septum, upper part of the later nasal wall, and the anterior part of nasal floor. No cauterizations or laser therapy were done during or after the procedure. The hemoglobin level and grades of epistaxis were recorded before and monthly after the procedure. The IFT grading system (intensity [I], frequency [F] of epistaxis, and the amount of blood transfusion [T]) and epistaxis severity score (ESS) for hereditary hemorrhagic telangiectasia system were used. Quality of life (QoL) was evaluated before and 4 weeks after the procedure using the Short Form\u201036 Health Survey questionnaire, Cantril's Self\u2010Anchoring Ladder questionnaire, and Slotosch disease\u2010specific QoL questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>A significant improvement was found in IFT grading (<jats:italic>P<\/jats:italic> = .007), ESS grading (<jats:italic>P<\/jats:italic> = .001), and hemoglobin level (<jats:italic>P<\/jats:italic> = .01). The QoL differences were statistically not significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The four\u2010injection site technique of intranasal administration of bevacizumab is an effective treatment option in HHT\u2010associated epistaxis, at least on the short\u2010term effect. Long\u2010term and comparative studies are needed to further evaluate the significance of this treatment modality. Laryngoscope, 2012<\/jats:p><\/jats:sec>","DOI":"10.1002\/lary.23303","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T11:33:36Z","timestamp":1332502416000},"page":"1210-1214","source":"Crossref","is-referenced-by-count":33,"title":["Bevacizumab in hereditary hemorrhagic telangiectasia\u2010associated epistaxis: Effectiveness of an injection protocol based on the vascular anatomy of the nose"],"prefix":"10.1002","volume":"122","author":[{"given":"Sinan","family":"Dheyauldeen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"\u00d8stertun Geirdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje","family":"Osnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv Sofie","family":"Vartdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Dollner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,7]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"40","article-title":"Natural history and control of epistaxis in a group of German patients with Rendu\u2010Osler\u2010Weber disease","volume":"43","author":"Folz BJ","year":"2005","journal-title":"Rhinology"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2500\/ajr.2008.22.3145"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-7865-y"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-011-1721-9"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2500\/105065899782102890"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/194589240501900113"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2011.03.003"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.79.927.18"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2010.07.001"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-006-0561-x"},{"key":"e_1_2_6_12_2","first-page":"575","article-title":"Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF?","volume":"22","author":"Sadick H","year":"2008","journal-title":"Int J Mol Med"},{"key":"e_1_2_6_13_2","first-page":"591","article-title":"Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia","volume":"15","author":"Sadick H","year":"2005","journal-title":"Int J Mol Med"},{"key":"e_1_2_6_14_2","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor\u2010beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick H","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20159"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0147-8"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21656"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21345"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20757"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21415"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","unstructured":"WhiteheadK ed. 9th International Hereditary Hemorrhagic Telangiectasia Scientific Conference May 20\u201324 2011. Kemer Antalya Turkey.Hematol Rep. [serial online]. May 2011. Available at:http:\/\/www.page press.org\/journals\/index.php\/hr\/article\/view\/hr.2011.s2.","DOI":"10.4081\/hr.2011.s2"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P"},{"key":"e_1_2_6_23_2","first-page":"281","article-title":"A grading scale for epistaxis in hereditary haemorrhagic teleangectasia","volume":"46","author":"Al\u2010Deen S","year":"2008","journal-title":"Rhinology"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2011.25.3616"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20818"},{"key":"e_1_2_6_26_2","volume-title":"SF\u201036 Health Survey Manual and Interpretation Guide","author":"Snowk K","year":"1993"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00083-3"},{"key":"e_1_2_6_28_2","volume-title":"The Pattern of Human Concerns","author":"Cantril H","year":"1965"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-933691"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2006.12.019"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.4193\/Rhino09.138"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-004-0911-0"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/194589240501900112"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/00016480802468138"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.4193\/Rhino10.090"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-011-1677-9"}],"container-title":["The Laryngoscope"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flary.23303","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.23303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T07:05:13Z","timestamp":1700550313000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lary.23303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/lary.23303"],"URL":"https:\/\/doi.org\/10.1002\/lary.23303","archive":["Portico"],"relation":{},"ISSN":["0023-852X","1531-4995"],"issn-type":[{"value":"0023-852X","type":"print"},{"value":"1531-4995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,7]]}}}